Accessibility Menu
ProtoKinetix logo

ProtoKinetix(OTC) PKTX

Current Price$0.01
Market Cap$2.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)+65%
5 Year-95%
1 Year-18%
1 Month+23%
ProtoKinetix last closing stock price
MetricPriceDate
Last closeUSD 0.012026-07-23
ProtoKinetix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.76%USD 0.012026-07-16
1 month+22.68%USD 0.012026-06-23
3 month+22.22%USD 0.012026-04-24
Year to date+10%USD 0.012025-12-31
1 year-17.5%USD 0.012025-07-23
3 year-74.62%USD 0.032023-07-21
5 year-94.92%USD 0.132021-07-23
Since inception+65%USD 0.002002-01-07

ProtoKinetix Financials at a Glance

Market Cap

$2.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$48.68K

Net Income (TTM)

-$376.18K

EPS (TTM)

-$0.00

P/E Ratio

-6.60

Dividend

$0.00

Beta (Volatility)

0.48 (Low)

Price

$0.01

Volume

2,500

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

May 13, 2026

PKTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ProtoKinetix

ProtoKinetix develops molecules to help protect cells in harsh conditions. Its research targets health problems like dry-eye disease. The company’s work aims to improve treatments for patients and healthcare providers.

Lab Bench to Bedside: What ProtoKinetix Makes

  • Anti-freeze glycoproteins: Molecules designed to protect cells from damage in extreme cold; 0% of revenue as no sales yet.
  • Anti-aging glycoproteins: Used in research for treating dry-eye disease; 0% of revenue, pre-commercial stage.
  • Patent portfolio: Intellectual property for glycoprotein technology; supports future healthcare applications.

Growth and Expansion: The ProtoKinetix Timeline

  • Formed a collaboration research agreement with University of British Columbia (agreement dated May 31, 2016).
  • Expanded patent portfolio, investing $29,019 in patent rights in first half of 2025.
  • Raised $167,500 in cash through private placement between April 2 and June 26, 2025.
  • No acquisitions or global market entries reported as of June 2025.

Why ProtoKinetix Is a Bit Different

Its main asset is proprietary glycoprotein technology. Academic partnerships drive its research progress.

Five Things You Need to Know

  • No revenue reported for any period through June 2025.
  • Net loss was $-91,067 in QQ2 2025, 7.0% lower than QQ2 2024.
  • Cash balance was $112 as of June 30, 2025.
  • Negative working capital of $-147,922 as of June 30, 2025.
  • Ongoing reliance on equity financing to fund operations.

Bottom Line

ProtoKinetix remains a research-focused company with no commercial products or revenue. Its future depends on developing and commercializing its glycoprotein technology.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Clarence Edward Smith

Website

www.protokinetix.com

Headquarters

Dalton, OH 45750, US

PKTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-86.22%

Return on Capital

-90.91%

Return on Assets

-57.30%

Earnings Yield

-15.15%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

391.58M

Volume

2.50K

Avg. Volume

40.18K

Financials (TTM)

Gross Profit

-$13.85K

Operating Income

-$363.51K

EBITDA

-$324.58K

Operating Cash Flow

-$181.18K

Capital Expenditure

-$5.15K

Free Cash Flow

-$160.47K

Cash & ST Invst.

$607.00

Total Debt

$0.00

ProtoKinetix Performance Analysis

ProtoKinetix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
ProtoKinetix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31-100.0%
Q22025-06-30N/A
Q32025-09-30N/A
ProtoKinetix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.01N/A
20222022-12-31USD -0.01-22.5%
20232023-12-31USD -0.00-80.6%
20242024-12-31USD -0.00-16.7%
ProtoKinetix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-50.0%
Q12025-03-31N/A
Q22025-06-30N/A
Q32025-09-30166.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$12.64K

+16.4%

Gross Margin

0.00%

N/A

Market Cap

$2.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$516.88K

N/A

Employees

5

N/A

Net Income

-$84.91K

-0.4%

EBITDA

-$72.27K

-4.0%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$607.00

-89.3%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-57.30%

N/A

Return on Invested Capital

-1.04%

N/A

Free Cash Flow

$26.76K

+843.2%

Operating Cash Flow

-$3.91K

+90.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZLDAFZelira Therapeutics Limited
$0.30+0.00%
AGNPFGrey Matters Health Inc.
$0.29+0.00%
AXIMAXIM Biotechnologies, Inc.
$0.00-10.31%
SIGYSigyn Therapeutics, Inc.
$0.03+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About PKTX

What is the current price of ProtoKinetix?

ProtoKinetix is trading at $0.01 per share.

What is the 52-week range for ProtoKinetix?

Over the past 52 weeks, ProtoKinetix has traded between $0.00 and $0.01.

How much debt does ProtoKinetix have?

As of the most recent reporting period, ProtoKinetix reported total debt of $0.00.

How much cash does ProtoKinetix have on hand?

ProtoKinetix reported $607.00 in cash and cash equivalents in its most recent financial results.

What is ProtoKinetix’s dividend yield?

ProtoKinetix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services